This category states: Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g., drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. This is a huge net
But - clinical trials aren't substantial, it's still not approved for use (indicating more safety data is warranted), most work is pre-clinical and or done with rodents not humans and given its ability to upregulate human growth hormone and angiogenesis (create new blood vessels), someone with a history of cancer would be advised to take serious precautions
These crystals are sharp and jagged on a microscopic level, and they can physically shred the delicate, complex structures of peptide molecules
The same applies to patients taking tetrathiomolybdate in clinical trials
It was first described in the scientific literature in 1993 by Sikiri and colleagues
BPC-157 Side Effects: What Is Normal, What Passes, and What to Watch BPC-157 has a strong preclinical safety profile across decades of animal research, and the side effect picture at clinical doses in supervised settings is generally mild